SelectQuote, Inc. SLQT used its fourth-quarter fiscal 2026 earnings call to put cash generation and leverage reduction ahead of near-term growth. Revenues for the reported quarter were $321.7 million, which missed the Zacks Consensus Estimate of $375 million. The company incurred a loss of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 15 cents.
Management focused on fiscal 2027, when it expects lower revenues, but materially higher operating cash flow as pharmacy margins improve and cost actions take hold.
SLQT Makes Cash Flow the Core Priority
Tim Danker, CEO and director, said profitable cash flow is the company's highest priority, with operating efficiency and lower leverage central to building shareholder value.
Ryan Clement, CFO, said fiscal 2026 operating cash flow improved by $44 million year over year to $31.9 million. For fiscal 2027, SelectQuote expects more than $60 million of operating cash flow and around $50 million of free cash flow.
Fourth-quarter adjusted EBITDA rose to $11.9 million from $2.7 million a year earlier even as revenue declined from $345.1 million.
SelectQuote Keeps MA Growth Disciplined
Danker said Medicare Advantage remains fluid as carriers work toward 3% to 4% operating margins. He expects continued plan terminations and benefit pullbacks while carrier profitability normalizes.
Clement said fiscal 2027 MA approved policies are expected to decline 10% to 15% year over year. Senior margins are expected to stay above the company's 20% target.
A Craig-Hallum analyst asked whether improving carrier signals could create upside. Danker said the market is healing, but pointed to plan year 2028 for a return to more responsible or targeted carrier growth.
SLQT Pushes Pharmacy Efficiency
Danker said Healthcare Services became SelectQuote's largest revenue contributor in fiscal 2026. SelectRx exited the year at a nearly $50 million annual adjusted EBITDA run rate.
Robert Grant, president, said the pharmacy facility in Olathe, Kan., is about 30% more efficient on shipments than legacy sites. Management also highlighted a custom pharmacy system and AI-enabled tools supporting more than $30 million of annual expense savings.
An RBC Capital Markets analyst asked about SelectRx growth outside Senior cross-selling. Grant said fiscal 2027 will prioritize margin and cash-flow efficiency, creating room to test third-party customer acquisition as economics improve.
SelectQuote Guides for Lower Revenues, Better Cash
Clement guided fiscal 2027 revenues to $1.35 billion to $1.45 billion and adjusted EBITDA to $90 million to $115 million. Revenues at the midpoint would be 14% below fiscal 2026.
Healthcare Services revenues are expected to fall 10-5%, primarily because of the Inflation Reduction Act. Clement said the revenue impact is more significant than the EBITDA impact and expects segment margins to approximately double.
Clement also expects SelectRx membership to finish fiscal 2027 around fiscal 2026 levels. Consolidated adjusted EBITDA margin is expected to expand about 60 basis points at the guidance midpoint.
SLQT Q&A Centers on Deleveraging
A NOBLE Capital Markets analyst pressed management on the more than $1 billion commissions receivable balance and longer-term cash generation. Clement said the balance should remain relatively flat through fiscal 2027 as collections are replenished by new policies.
Danker said debt and preferred equity total around $800 million at an approximate 12% cost. A 100-basis-point reduction in that funding cost would translate to nearly $8 million of savings.
When NOBLE asked about securitization and capital allocation, Clement said the short-term probability of another receivables securitization is relatively low. He prioritized deleveraging and high-return investments that enhance cash generation.
SelectQuote Ends on Execution Discipline
Danker closed by emphasizing cash flow over growth for its own sake. The fiscal 2027 plan centers on efficiency, disciplined Senior investment and stronger Healthcare Services profitability.
Clement's outlook pairs lower top-line expectations with higher cash generation, while management keeps refinancing, debt reduction and funding-cost optimization in focus.
SLQT's Zacks Signals Stay Mixed
SLQT carries a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of F, Momentum Score of A and VGM Score of C. Under the Zacks framework, Value is the strongest element and Momentum the weakest. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores complement the Zacks Rank, with A and B grades preferred and the strongest combinations generally pairing those scores with a Zacks Rank #1 or 2 (Buy). SLQT's Zacks Rank can change as earnings estimates are revised after the newly reported results.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SelectQuote, Inc. (SLQT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
